
SANTA CRUZ BIOTECHNOLOGY, INC.

LOC729287 (N-14): sc-84167



BACKGROUND

Comprising nearly 4% of human DNA, chromosome 13 contains around 114 million base pairs and 400 genes. Key tumor suppressor genes on chromosome 13 include the breast cancer susceptibility gene, BRCA2, and the RB1 (retinoblastoma) gene. RB1 encodes a crucial tumor suppressor protein which, when defective, leads to malignant growth in the retina and has been implicated in a variety of other cancers. The gene SLITRK1, which is associated with Tourette syndrome, is on chromosome 13. As with most chromosomes, polysomy of part or all of chromosome 13 is deleterious to development and decreases the odds of survival. Trisomy 13, also known as Patau syndrome, is quite deadly and the few who survive past one year suffer from permanent neurologic defects, difficulty eating and vulnerability to serious respiratory infections. The LOC729287 gene product has been provisionally designated LOC729287 pending further characterization.

REFERENCES

- Dunham, A., Matthews, L.H., Burton, J., Ashurst, J.L., Howe, K.L., Ashcroft, K.J., Beare, D.M., Burford, D.C., Hunt, S.E., Griffiths-Jones, S., Jones, M.C., Keenan, S.J., Oliver, K, et al. 2004. The DNA sequence and analysis of human chromosome 13. Nature 428: 522-528.
- Deng, H., Le, W.D., Xie, W.J. and Jankovic, J. 2006. Examination of the SLITRK1 gene in Caucasian patients with Tourette syndrome. Acta Neurol. Scand. 114: 400-402.
- Giacinti, C. and Giordano, A. 2006. RB and cell cycle progression. Oncogene. 25: 5220-5227.
- Grados, M.A. and Walkup, J.T. 2006. A new gene for Tourette's syndrome: a window into causal mechanisms? Trends Genet. 22: 291-293.
- Bugge, M., Collins, A., Hertz, J.M., Eiberg, H., Lundsteen, C., Brandt, C.A., Bak, M., Hansen, C., Delozier, C.D., Lespinasse, J., Tranebjaerg, L., Hahnemann, J.M., Rasmussen, K., Bruun-Petersen, G., Duprez, L., Tommerup, N. and Petersen, M.B. 2007. Non-disjunction of chromosome 13. Hum. Mol. Genet. 16: 2004-2010.
- Hall, H.E., Chan, E.R., Collins, A., Judis, L., Shirley, S., Surti, U., Hoffner, L., Cockwell, A.E., Jacobs, P.A. and Hassold, T.J. 2007. The origin of trisomy 13. Am. J. Med. Genet. A 143: 2242-2248.
- Hassler, M., Singh, S., Yue, W.W., Luczynski, M., Lakbir, R., Sanchez-Sanchez, F., Bader, T., Pearl, L.H. and Mittnacht, S. 2007. Crystal structure of the retinoblastoma protein N domain provides insight into tumor suppression, ligand interaction and holoprotein architecture. Mol. Cell 28: 371-385.
- Hsu, H.F. and Hou, J.W. 2007. Variable expressivity in Patau syndrome is not all related to trisomy 13 mosaicism. Am. J. Med. Genet. A 143: 1739-1748.
- 9. Thorslund, T. and West, S.C. 2007. BRCA2: a universal recombinase regulator. Oncogene 26: 7720-7730.

CHROMOSOMAL LOCATION

Genetic locus: LOC729287 (human) mapping to 13q21.31.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

SOURCE

L0C729287 (N-14) is an affinity purified rabbit polyclonal antibody raised against a peptide mapping at the N-terminus of L0C729287 of human origin.

PRODUCT

Each vial contains 100 μg lgG in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

Blocking peptide available for competition studies, sc-84167 P, (100 μ g peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% BSA).

APPLICATIONS

L0C729287 (N-14) is recommended for detection of L0C729287 of human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

Suitable for use as control antibody for LOC729287 siRNA (h): sc-106088, LOC729287 shRNA Plasmid (h): sc-106088-SH and LOC729287 shRNA (h) Lentiviral Particles: sc-106088-V.

Molecular Weight of LOC729287: 3.75 kDa.

RECOMMENDED SECONDARY REAGENTS

To ensure optimal results, the following support (secondary) reagents are recommended: 1) Western Blotting: use goat anti-rabbit IgG-HRP: sc-2004 (dilution range: 1:2000-1:100,000) or Cruz Marker[™] compatible goat anti-rabbit IgG-HRP: sc-2030 (dilution range: 1:2000-1:5000), Cruz Marker[™] Molecular Weight Standards: sc-2035, TBS Blotto A Blocking Reagent: sc-2333 and Western Blotting Luminol Reagent: sc-2048. 2) Immunofluo-rescence: use goat anti-rabbit IgG-FITC: sc-2012 (dilution range: 1:100-1:400) or goat anti-rabbit IgG-TR: sc-2780 (dilution range: 1:100-1:400) with UltraCruz[™] Mounting Medium: sc-24941.

STORAGE

Store at 4° C, **D0 NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

PROTOCOLS

See our web site at www.scbt.com or our catalog for detailed protocols and support products.